<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402610</url>
  </required_header>
  <id_info>
    <org_study_id>GAEI 94/0071a</org_study_id>
    <secondary_id>FIS 94/0071A</secondary_id>
    <nct_id>NCT00402610</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy</brief_title>
  <official_title>A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Andaluza de Enfermedades Infecciosas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sociedad Andaluza de Enfermedades Infecciosas</source>
  <brief_summary>
    <textblock>
      INTRODUCTION. To evaluate the efficacy of three regimens of prophylactic therapy for
      tuberculosis in HIV-infected patients with anergy. METHODS. Prospective, multi-center,
      randomized, comparative, and open clinical trial. Anergy was defined as absence of induration
      in response to three antigens (PPD, Candida albicans and parotiditis antigen) applied by the
      Mantoux method. Patients were randomized into one of the following prophylactic treatment
      groups: isoniazid for six months (6H), rifampin plus isoniazid for three months (3RH),
      rifampin plus pyrazinamide for two months (2RZ) or no treatment (NT). After completion of
      treatment, patients were followed up for two years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a controlled, open, randomized, multi-center clinical trial. The study was
      authorized by the Clinical Research Ethics Committee of all participating centers and
      informed written consent was obtained from all the patients included. The cutaneous anergy
      was defined by the absence of a reaction (0 mm) to skin reactivity tests with tuberculin,
      Candida albicans, and parotiditis antigens 72 hours after inoculation. The patients were
      randomzed into one of the following four groups: isoniazid for 6 months (6H), rifampin plus
      isoniazid for 3 months (3RH), rifampin plus pyrazinamide for 2 months (2RZ) or no treatment
      (NT). All of the participating subjects underwent a basal study that included clinical and
      epidemiological history, chest x-ray, hemogram, analysis of serum creatinine concentrations,
      uric acid, AST, ALT, alkaline phosphatase, and total bilirubin, as well as a CD4+
      T-lymphocyte count.During prophylactic treatment, patients were evaluated every 15 days for
      the first two months and monthly thereafter. At each check-up it was determined whether or
      not the patient was following the treatment properly and whether there were any adverse
      effects. Therapeutic completion was defined as taking at least 80% of the total prescribed
      dosages.Chemoprophylaxis was discontinued whenever a patient requested to do so or for any of
      the following reasons: appearance of Grade 3 or 4 side effects that could be attributed to
      the drugs used in the study; increases in AST and/or ALT values of three times or more their
      basal values; development of TB; or diagnosis of any disease that made interruption of the
      treatment advisable.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1994</start_date>
  <completion_date>December 1998</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of tuberculosis</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suspension of chemoprophylaxis due to adverse effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
  </secondary_outcome>
  <enrollment>332</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection confirmed by ELISA and Western blot

          -  Age between 18 and 65 years

          -  Life expectancy greater than two years

          -  Cutaneous anergy defined by the absence of a reaction (0 mm) to skin reactivity tests
             with tuberculin, Candida albicans, and parotiditis antigens 72 hours after
             inoculation.

        Exclusion Criteria:

          -  Presence of active tuberculosis

          -  Background of previous antituberculosis therapy or chemoprophylaxis

          -  Presence of symptoms or signs suggesting pulmonary or extra-pulmonary tuberculosis

          -  History of hypersensitivity to the drugs used in the study (isoniazid, rifampin or
             pyrazinamide)

          -  Aspartate-aminotransferase and/or alanine-aminotransferase plasma concentrations more
             than or equal to four times their normal values, total bilirubin more than 2 mg/ml,
             and/or creatinine more than 2 mg/ml

          -  Pregnancy

          -  Undergoing treatment incompatible with any of the drugs used in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Rivero, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Reina Sofía, Córdoba, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Lopez-Crtés, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen del Rocío, Sevilla, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Castillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>3 Sección de Enfermedades Infecciosas. Hospital Clínico Universitario San Cecilio. Avda. Dr. Oloriz 16. 18012 Granada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Verdejo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Enfermedades Infecciosas. Hospital Carlos III. Sinesio Delgado 10. 28029 Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Angel García, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sección de Enfermedades Infecciosas. Hospital Carlos Haya. Avda. Carlos Haya s/n. 29010 Málaga.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipes Diez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Medicina Interna. Hospital Torrecárdenas. Paraje de Torrecárdenas s/n. 04009 Almería.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Carlos Escribano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sección de Enfermedades Infecciosas. Hospital Universitario Puerta del Mar. Avda. Ana de Viya, 21. 11009 Cádiz. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Canueto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sección de Enfermedades Infecciosas. Hospital Punta Europa de Algeciras. Ctra de Getares s/n. 11207 Algeciras (Cádiz)., Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Marquez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad de Enfermedades Infecciosas. Hospital Universitario Virgen de la Victoria, Campus Universitario Teatinos s/n. 29010 Málaga.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Jose Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad de Enfermedades Infecciosas. Hospital Ciudad de Jaén, Avda del Ejército Español, 10. 23007 Jaén, Spain.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Pasquau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sección de Enfermedades Infecciosas. Hospital Universitario Virgen de las Nieves. Avda de las Fuerzas Armadas, 2. 18014 Granada, Spain.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Lozano, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sección de Enfermedades Infecciosas. Hospital Universitario Virgen de Valme. Ctra. de Cádiz s/n. 41012 Sevilla, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Rivero A, López-Cortés L, Castillo R, Lozano F, García MA, Díez F, Escribano JC, Canueto J, Pasquau J, Hernández JJ, Polo R, Martínez-Marcos FJ, Kindelán JM, Rey R; Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI). [Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy]. Enferm Infecc Microbiol Clin. 2003 Jun-Jul;21(6):287-92. Spanish.</citation>
    <PMID>12809582</PMID>
  </results_reference>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>October 23, 2008</last_update_submitted>
  <last_update_submitted_qc>October 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2008</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Chemoprophylaxis</keyword>
  <keyword>Anergy</keyword>
  <keyword>AIDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

